Project Grant R44CA295197
Award Date
9/1/24
Completion Date
8/31/27
Dollars Obligated
$857K
Federal Agency
National Cancer Institute
Awardee
Creosalus Inc. (CBL5M5DKH3K7)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
The National Cancer Institute (NCI) awarded a $1,200,000 Project Grant under CFDA 93.395 - Cancer Treatment Research to Creative Biotherapeutics LLC, a biotechnology research firm, to develop a novel biologic therapy to eradicate brain cancer and brain metastases. The funded research aims to target the extracellular glucose-regulated protein 78 (eGRP78) expressed on the surface of drug-resistant tumor cells, in order to induce apoptosis, eliminate drug and immune resistance, and reduce the...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
This $399,358 Project Grant awarded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Cordance Medical Inc. aims to optimize a non-invasive focused ultrasound system, called the "NeuroAccess System," to enable liquid biopsies for brain tumor patients. The key objectives are to demonstrate the safety of repeatedly opening the blood-brain barrier, optimize the opening volume and technique in a rat glioma model, and confirm the system's ability to...
This $381,100 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports the development and evaluation of tumor-targeting polymeric micelles carrying a near-infrared (NIR) imaging agent. The goal is to provide real-time optical image guidance during brain cancer surgery to improve tumor resection and surgical outcomes. The project aims to: 1) develop and characterize the tumor-targeting polymeric...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) provides $163,640 to the University of Virginia to develop novel non-viral gene delivery platforms for the treatment of glioblastoma, an aggressive brain cancer. The research aims to improve the therapeutic accumulation and delivery of gene therapies by leveraging brain-penetrating nanoparticles and focused ultrasound technology. Key objectives include investigating the tumor-targeting and...
The National Cancer Institute (NCI) awarded a $456,414 Project Grant under CFDA 93.395 - Cancer Treatment Research to Seattle Children's Hospital, doing business as Seattle Children's Research Institute, to conduct a phase 2 clinical trial of B7-H3 chimeric antigen receptor (CAR) T-cell therapy for children and young adults with diffuse intrinsic pontine glioma (DIPG), a fatal central nervous system tumor. The award will support the delivery of repeatedly dosed, locoregional B7-H3 CAR T cells at...
This federal Project Grant award of $374,095 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a device that uses an infrared laser to enable local delivery of a high dose of chemotherapy to the surgical cavity after tumor resection. The technology employs thermosensitive liposomal nanoparticles encapsulating chemotherapy agents that...
The National Cancer Institute (NCI) awarded a $679,176 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the University of Texas at Dallas (UTD) to develop a novel and minimally invasive method to enhance spinal cord delivery of cancer therapies. The key products and services to be delivered under this 5-year award include: Characterizing the blood-spinal cord barrier (BSCB) and utilizing epidural light-based techniques (OptoBSCB) to temporarily and...